Regulating RAS Activity to Target RAS-Driven Cancers
The status, timeline and source of this project. A free account opens every field.
Source: EU Funding & Tenders Portal
More than a quarter of all cancers are driven by mutations in the RAS family of genes. Considering the key role of these oncogenes, and despite intensive effort, no effective anti-RAS strategies have successfully made it to the clinic. In our ERC-CoG project, we found that a class of scaffold proteins, expressed in cancer, bind to active/mutated forms of RAS proteins to moderate RAS signalling. Ac
- Status
- Closed
- Sector
- Hospital, Commercial
- Location
- Finland
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Regulating RAS Activity to Target RAS-Driven Cancers
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | More than a quarter of all cancers are driven by mutations in the RAS family of genes. Considering the key role of these oncogenes, and despite intensive effort, no effective anti-RAS strategies have successfully made it to the clinic. In our ERC-CoG project, we found that a class of scaffold proteins, expressed in cancer, bind to active/mutated forms of RAS proteins to moderate RAS signalling. Accordingly, we find that loss of one of the scaffolding protein isoforms in RAS-mutant cancers triggers cytotoxic signalling, leading to cell death. As such, drugging this scaffold protein could not only i) represent a completely innovative approach to target RAS-driven cancers that exploits the oncogene’s function, but also ii) deliver the first truly effective cancer treatment for patients that do not respond to current standards of care. In this ERC-PoC, we aim to prove that therapeutic targeting of the scaffold protein is effective in vivo, and to explore the commercial avenues to exploit this finding. |
Location
Country | Finland |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital, Commercial |
Article published date | 2026-02-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
